Date of Award

5-17-2024

Document Type

Thesis

Abstract

Breast cancer is the most common form of cancer in the world. In 2023, nearly 300,000 new cases of breast cancer were projected in the U.S. alone. When treating breast cancer, several therapies are utilized, often including chemotherapy. Organoplatinum(IV) complexes are among the newer chemotherapy drugs being developed as an alternative to cisplatin, the first platinumbased anticancer drug. Two novel organoplatinum(IV) complexes: [Pt(CH₃)₂X₂{bipy-(CO₂H)₂}] (X = Br, I) have been isolated and structurally characterized by single-crystal X-ray diffraction. Nuclear magnetic resonance and infrared spectroscopic data were also collected to confirm these new compounds and provide useful reference values. The anticancer potential of each compound was assessed via in vitro 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assays using human breast cancer cells (cell line ZR-75-1). EC₅₀ values were determined as 3020 μM, for Pt(CH₃)₂Br₂{bipy-(CO₂H)₂} and 86.0 μM, for Pt(CH₃)₂I₂{bipy-(CO₂H)₂}; for comparison, the EC₅₀ value for cisplatin against the ZR 75-1 cells was 16.4 μM. While these compounds were not as effective as cisplatin, the single-crystal X-ray diffraction data showed evidence of intermolecular π-π interactions within the unit cell which suggest that the bipyridyl ligands can potentially interact with tumor DNA nucleobases in the DNA double helix.

Handle

http://hdl.handle.net/11122/15136

Download

Share

COinS